ArticleFrontiers in public health2026

Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma.

Mengmeng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.